Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Treatment Resistant Depression
Phase PHASE2
Enrollment 142
Locations 48 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: VLS-01-203 BU — VLS-01 buccal transmucosal administration
  • Drug: VLS-01-BU Placebo — Placebo buccal transmucosal administration

Primary Outcomes

  • Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score (Baseline to Day 29)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-30
Completion: 2026-08-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 142 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: atai Therapeutics, Inc.
Contact Information
Study Contact:
Kevin Craig, MD
332-282-0507
clinicaltrials@atai.life
Interventions
  • Drug: VLS-01-203 BU — VLS-01 buccal transmucosal administration
  • Drug: VLS-01-BU Placebo — Placebo buccal transmucosal administration
Study Locations (48 sites)
Noble Clinical Research, Tucson, Arizona 85704 United States
Pillar Clinical Research, LLC, Little Rock, Arkansas 72204 United States
Preferred Research Partners, Inc., Little Rock, Arkansas 72211 United States
Woodland Research Northwest, Rogers, Arkansas 72758 United States
CenExel, Garden Grove, California 92845 United States
Behavioral Research Specialists, LLC, Glendale, California 91206 United States
Kadima Neuropsychiatry Institute, La Jolla, California 92037 United States
Collaborative Neuroscience Research, LLC, Los Alamitos, California 90720 United States
TRIP Clinical at Psychedelic Science Institute, Santa Monica, California 90404 United States
Mountain View Clinical Research Inc., Denver, Colorado 80209 United States
Eligibility Criteria
Inclusion Criteria: * Participant must be 18 to 65 years of age inclusive at the time of signing the Informed Consent. * Has a diagnosis of recurrent moderate or severe MDD without psychotic features or single- episode MDD with duration greater than or equal to 3 months without psychotic features and is currently experiencing a major depressive episode. * Onset of first episode of MDD occurred before age 55. * Has not responded to an adequate dose and duration of at least two and no more than five antidepressant medications for the current depressive episode, as determined by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH- ATRQ). * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. Exclusion Criteria: * Has a current or prior DSM-5-TR diagnosis of a schizophrenia spectrum and other psychotic disorder, substance/medication-induced psychotic disorder, bipolar and related disorder, or any disorder with psychotic features. * Has a moderate or severe substance use disorder (drug, alcohol, or tobacco) within the 6 months before Screening and/or history of moderate or severe substance use disorder (drug alcohol) within the previous 1 year before Screening * Has a history of, or current signs and symptoms of, diseases or conditions that would make participation not be in the best interest (e.g., compromise the wellbeing) of the participant or that could prevent, limit, or confound the protocol-specified assessments. * Has suicidal ideation with some intent to act within 6 months before Screening or a history of suicidal behavior within the past 1 year before Screening. * Has a history of clinically significant cardiovascular, cerebrovascular, or peripheral vascular disease or condition, including but not limited to unstable angina, myocardial infarction, congestive heart failure, cardiac arrhythmia, valvular heart disease, obstructive coronary artery disease, hypertension, hypotension, bradycardia, tachycardia, or risk factors for long QT Syndrome. * Has an active malignancy, or history of malignancy, excluding basal or squamous cell carcinoma of the skin, within 2 years before Screening. * Has any known allergy or hypersensitivity to VLS-01 or to any of the excipients in the formulation. * Has recently initiated and is currently undergoing directive psychotherapy (e.g., cognitive behavioral therapy, interpersonal psychotherapy, psychodynamic psychotherapy) within the past 30 days before Screening. Participants planning to initiate individual or group therapy during the study are also not eligible. * Has received any prohibited therapies. * Has clinically significant laboratory abnormalities at Screening.
Conditions Emotional Disorders, Depressive Disorder...
Phase NA
Enrollment 464
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are: * Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years? * Is this combined approach more cost-effective than usual care alone? Researchers will compare the group receiving the digital mindfulness intervention plus their usual treatment to the group receiving only their usual treatment to see if the intervention leads to better long-term recovery and represents good value for money. Participants in the intervention group will: * Attend eight weekly 2-hour online group mindfulness sessions. * Use a WeChat mini-program for 49 days of guided mindfulness exercises and daily tasks. * Patients who have not achieved reliable recovery after group retraining voluntarily participate in individual UP\&MIED counseling. * Complete regular questionnaires and interviews over two years to track their progress. All participants will continue to receive their usual medical care from their doctors throughout the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mindfulness Intervention for Emotional Distress — MIED is a psychological intervention program based on "Mindfulness-Based Stress Reduction" (MBSR) and the "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP), proposed by one of our authors. It includes a psychological diamond model of emotional distress and core intervention strategies (Liu, 2024). This program, in the form of mental health education courses, is suitable for patients with emotional disorders such as anxiety and depression. It has shown good effects in alleviating emotional distress in a series of preliminary studies (Ju et al., 2022; Li et al., 2023; Li et al., 2025; Wang et al., 2024). In this study, the intervention mainly adopts a step-care model, dynamically adjusting the intensity of the intervention according to the patient's recovery progress. All intervention content revolves around the four core transdiagnostic mechanisms of the MIED psychological diamond model and their corresponding core intervention strategies.

Primary Outcomes

  • Time to Reliable Recovery (at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-23
Completion: 2028-05
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 464 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Collaborators: WU'AN FIRST PEOPLE'S HOSPITAL, Xi'an Mental Health Center, The Second Hospital of Anhui Medical University, The Guangxi Zhuang Autonomous Region Brain Hospital, DONG GUAN SEVENTH PEOPLE'S HOSPITAL, Affiliated Mental Health Center of Kunming Medical University, People's Hospital of Zhengzhou University, The Affiliated Brain Hospital of Guangzhou Medical University, THE SIXTH AFFILIATED HOSPITAL OF GUANGDONG PHARMACEUTICAL UNIVERSITY, Xiamen Medical College Affiliated Xian Yue Hospital
Principal Investigators:
  • Xinghua Liu (PRINCIPAL_INVESTIGATOR) - School of Psychological and Cognitive Sciences,Peking University
Contact Information
Study Contact:
Dongyang Chen
+8618810673387
psychen@stu.pku.edu.cn
Elena Gomzyakova
+8618665380155
lenagom@stu.pku.edu.cn
Dongyang Chen
86-18810673387
psychen@stu.pku.edu.cn
Peking University
Interventions
  • Behavioral: Mindfulness Intervention for Emotional Distress — MIED is a psychological intervention program based on "Mindfulness-Based Stress Reduction" (MBSR) and the "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP), proposed by one of our authors. It includes a psychological diamond model of emotional distress and core intervention strategies (Liu, 2024). This program, in the form of mental health education courses, is suitable for patients with emotional disorders such as anxiety and depression. It has shown good effects in alleviating emotional distress in a series of preliminary studies (Ju et al., 2022; Li et al., 2023; Li et al., 2025; Wang et al., 2024). In this study, the intervention mainly adopts a step-care model, dynamically adjusting the intensity of the intervention according to the patient's recovery progress. All intervention content revolves around the four core transdiagnostic mechanisms of the MIED psychological diamond model and their corresponding core intervention strategies.
Study Locations (1 sites)
Peking University, Beijing, China
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-65 years. 2. Diagnosed with an emotional disorder by a outpatient psychiatrist, including depressive disorders, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder), obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders (e.g., anorexia nervosa, bulimia nervosa). 3. Symptom severity meeting the threshold: PHQ-9 score ≥10 or GAD-7 score ≥8. Exclusion Criteria: 1. Current diagnosis of psychotic disorders or bipolar disorder. 2. Current organic mental disorders, pervasive developmental disorders, severe cognitive impairment, or substance use disorders. 3. Current suicide risk (PHQ-9 item 9 score \>2). 4. Antisocial personality disorder. 5. Severe medical illnesses that may affect intervention participation or require recent hospitalization. 6. Previous participation in a systematic 8-week mindfulness course. 7. Inability to access the internet.
Conditions Treatment Resistant Major Depression
Phase PHASE4
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all affiliated with MUSC and within 2-hours driving from Charleston, SC. This study would test out this new delivery mode, and provide valuable feasibility, safety, and efficacy lessons for later refinement and potential widespread adoption of mobile TMS as a treatment option, both in our state and across the US.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Left prefrontal Transcranial Magnetic Stimulation (TMS) — FDA cleared TMS
  • Device: FDA cleared TMS for treating depression — This is FDA approved TMS

Primary Outcomes

  • Percent of depression responders (From baseline to 1 week immediately after treatment week)
  • Improvement in Depression Symptoms (From baseline to 1 week immediately after treatment week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-05-10
Completion: 2028-03-01
Eligibility
Age: 22 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Principal Investigators:
  • Mark George, MD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Mark S George, MD
8438765142
GEORGEM@MUSC.EDU
Alexandra Herron, BA
herronal@musc.edu
Mark S. George, MD
8438765142
GEORGEM@MUSC.EDU
Medical Univerity of South Carolina
Interventions
  • Device: Left prefrontal Transcranial Magnetic Stimulation (TMS) — FDA cleared TMS
  • Device: FDA cleared TMS for treating depression — This is FDA approved TMS
Study Locations (1 sites)
Medical Univerity of South Carolina, Charleston, South Carolina 29425 United States
Eligibility Criteria
Inclusion Criteria: * Adult (22-80 years old) * Have treatment-resistant depression as defined by the e-Mini, and the antidepressant treatment history form (ATHF short). * Be able to read and communicate in English. * Able to provide their own consent. * Access to a computer with videoconferencing ability for initial consent and telescreen. Exclusion Criteria: * Patients with unstable medical conditions that might make TMS unsafe. This includes current poorly controlled seizures. * Ferromagnetic metal in the head. * Pregnant. * Currently active substance abuse except tobacco.
Conditions Insufficient Sleep, Hypertension
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Determine the effectiveness and feasibility of a mobile health sleep extension approach in the pediatric nephrology setting, to increase sleep duration and reduce systolic and diastolic blood pressure.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Intervention — During a 7-week intervention phase, parent-child dyads will be provided a sleep duration goal paired with a loss-framed financial incentive (virtual account) starting with deductions each time the sleep goal is not met, will be sent sleep guidance text messages, and will receive weekly performance feedback text messages.

Primary Outcomes

  • Hypertension (From baseline to approximately week 11)
  • Change in sleep tracker estimated weeknight sleep duration (From baseline to approximately week 11)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-16
Completion: 2026-11
Eligibility
Age: 13 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital of Philadelphia
Principal Investigators:
  • Jonathan Mitchell, PhD (PRINCIPAL_INVESTIGATOR) - Children's Hospital of Philadelphia
Contact Information
Study Contact:
Jonathan Mitchell
267-426-1473
mitchellj2@chop.edu
Abby Salem
215-590-2386
salema1@chop.edu
Jonathan Mitchell
267-426-1473
mitchellj2@chop.edu
Children's Hospital of Philadelphia
Interventions
  • Behavioral: Intervention — During a 7-week intervention phase, parent-child dyads will be provided a sleep duration goal paired with a loss-framed financial incentive (virtual account) starting with deductions each time the sleep goal is not met, will be sent sleep guidance text messages, and will receive weekly performance feedback text messages.
Study Locations (1 sites)
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19146 United States
Eligibility Criteria
Inclusion Criteria: * Speak, read and write in English. * Parental/guardian permission (informed consent) and child assent. * Have a computer or a tablet computer with access to the Internet or own a smartphone with a data and text plan. * Parent reported sleep duration on school nights less than or equal to 7.5 hours. * Recently diagnosed with essential hypertension by Ambulatory Blood Pressure Monitoring (ABPM). * If taking over the counter sleep aides, willing to stop them over the course of the study. Exclusion Criteria: * Any clinically diagnosed sleep disorder (e.g. sleep apnea) in the electronic health record and or regular use of prescribed sleep aide. * Underlying chronic medical conditions, defined as a medical condition with a duration or expected duration longer than 3 months that involved taking regular medication, taking medications that could affect blood pressure (e.g., anti-hypertensive medications, glucocorticoids, or stimulants), and patients with underlying diagnoses known to be associated with elevated blood pressure (e.g., cardiac disease, kidney disease or diabetes). Inclusion Criteria for Parents/Legal Guardians: * Be the parent/guardian of an eligible child enrolled in the main study. * Speak, read, and write in English. Exclusion Criteria for Parents/Legal Guardians: \- Limited English proficiency
Conditions Pre-capillary Pulmonary Hypertension
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to understand how blood cell (including peripheral blood mononuclear cells ((PBMCs) or platelets) function and oxidative stress can help physicians detect and predict the course of pre-capillary pulmonary hypertension. We hypothesize that changes in the mitochondrial function of blood cells and oxidative stress may be early markers of disease progression and severity. The study will also explore how these blood markers relate to routine clinical and heart function measurements, such as echocardiography, right heart catheterization, 6-minute walk tests, and functional status, to see if they can help monitor patients over time and guide personalized care. This is a non-interventional study. Blood samples will be collected during routine visits planned for diagnosis and follow-up. The study will include 120 patients diagnosed with pre-capillary pulmonary hypertension, who will be followed for 3 years. Blood samples will be taken up to three times per year to measure mainly oxidative stress and mitochondrial function in blood cells. These measurements will be compared with clinical tests to see if they can help predict the course of the disease.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Patients with pre-Capillary pulmonary hypertension — Patients will be followed for 3 years with routine clinical, hemodynamic, and laboratory assessments. Blood samples for oxidative stress and mitochondrial function analyses will be collected during scheduled follow-up visits or catheterization procedures. No intervention beyond standard care will be performed.

Primary Outcomes

  • Blood Cell Mitochondrial Function and Respiration and Oxidative Stress Markers (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Strasbourg, France
Principal Investigators:
  • Marianne RIOU (PRINCIPAL_INVESTIGATOR) - Hôpitaux Universitaires de Strasbourg
Contact Information
Study Contact:
Marianne RIOU
+ 33 3 69 55 11 45
marianne.riou@chru-strasbourg.fr
Marianne RIOU
+33 3 69 55 11 45
marianne.riou@chru-strasbourg.fr
Hôpitaux Universitaires de Strasbourg - Service Physiologie explorations fonctionnelles
Interventions
  • Other: Patients with pre-Capillary pulmonary hypertension — Patients will be followed for 3 years with routine clinical, hemodynamic, and laboratory assessments. Blood samples for oxidative stress and mitochondrial function analyses will be collected during scheduled follow-up visits or catheterization procedures. No intervention beyond standard care will be performed.
Study Locations (1 sites)
Hôpitaux Universitaires de Strasbourg - Service Physiologie explorations fonctionnelles, Strasbourg, Bas-Rhin 67000 France
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥18 years) diagnosed with pre-capillary pulmonary hypertension confirmed by right heart catheterization * Patients classified according to the international clinical classification: * Group 1: Pulmonary arterial hypertension (PAH) * Group 3: Pulmonary hypertension associated with chronic respiratory diseases and/or hypoxia * Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) * Patients scheduled for routine clinical follow-up and/or right heart catheterization at the study center. * Ability and willingness to provide informed consent for participation and data analysis. Exclusion Criteria: * Postcapillary pulmonary hypertension (pulmonary arterial wedge pressure \>15 mmHg). * Conditions precluding safe blood sampling (e.g., severe anemia, coagulopathy). * Patients already enrolled in interventional clinical trials that could interfere with mitochondrial or oxidative stress measurements * Patients unable or unwilling to provide informed consent * Pregnancy or breastfeeding
Conditions Hypertension
Phase NA
Enrollment 81
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Since Hypertension affects all body systems and importantly postural balance control. So, the evidence indicates a strong link and connection between balance and hypertension through somatosensory, visual, vestibular, musculoskeletal, and CNS integration of inputs from both peripheral and motor systems. Therefore, to fill this gap of how much balance and each of its aspects/components are affected, this study will be done for a detailed examination of this genuine integration and clinical interaction among hypertensive with game-based techniques on all three balance components (concerning Intensity, frequency, duration and dosage of VRET). Secondly, on the other hand (CR) programs, have shown very low compliance with recommended Physical Activity, which is why; by utilising this alternative, Virtual reality exergaming can be used as a quick, appropriate and equivalent alternative to traditional exercise programs. Also, in future, it could be suggested with promising effects in the provision of engaging, goal-oriented training for patients with hypertensive besides a sound, economical and clinically beneficial alternative to traditional Cardiac Rehabilitation. Finally, by exploring detailed clinical integration of Postural Balance with Hypertension using Virtual Reality the study will be able to highlight hypertension as a potent risk factor for future impaired balance and risks of falls. Thereby, hypertension's early identification (considering all biological, psychological, and social factors) and prevention may avert hypertensive to future debilitating complications and outcomes as a result of it.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Exercise — The participants would be playing exergames using XBOX-360 Kinect. Multiple games would be selected for the participants to play. The player would be upgraded to next levels of games after completing the initial levels.
  • Other: Exercise — The subjects would be doing treadmill training within moderate intensity target heart rate.
  • Other: No intervention — The subjects would not be given any intervention and would be used as controls.

Primary Outcomes

  • Gait and Balance App (Baseline before provision of interventions)
  • Gait and Balance App (After 4 weeks of interventions)
  • Gait and Balance App (After 8 weeks of interventions)
  • Brain-derived neurotrophic factor (BDNF) biomarker: (Baseline before provision of interventions)
  • Brain Derived Neurotrophic Factor Biomarker (After 8 weeks of interventions)
  • Exercise Enjoyment Questionnaire (EEQ) (After 8 weeks of interventions)
  • The Montreal Cognitive Assessment (MoCA) (Baseline before provision of interventions)
  • Montreal Cognitive Assessment (MoCA) (After 4 weeks of interventions)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-16
Completion: 2025-11-01
Eligibility
Age: 20 Years – 55 Years
Sex: ALL
Volunteers: false
Enrollment: 81 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Riphah International University
Principal Investigators:
  • Imran Amjad, PhD (PRINCIPAL_INVESTIGATOR) - Riphah International University Islamabad
Contact Information
Study Contact:
Sana Bashir, MS-CPPT
+92 3218529475
sana.bashir65@gmail.com
Imran Amjad, PhD
+92 3324390125
imran.amjad@riphah.edu.pk
Sana Bashir
Foundation University
Interventions
  • Other: Exercise — The participants would be playing exergames using XBOX-360 Kinect. Multiple games would be selected for the participants to play. The player would be upgraded to next levels of games after completing the initial levels.
  • Other: Exercise — The subjects would be doing treadmill training within moderate intensity target heart rate.
  • Other: No intervention — The subjects would not be given any intervention and would be used as controls.
Study Locations (1 sites)
Foundation University, Islamabad, Federal 44000 Pakistan
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of Community dwelling controlled Hypertensive (particularly Stage 1, 130 to 139 (systolic) or 80 to 89 (diastolic) or Stage 2 hypertension from 140 or higher (systolic) or 90 (diastolic) if present with any (controlled diabetes or overweight patients) with a medical referral form for medical specialist with physiotherapeutic treatment provided by the local public or private healthcare system 2. Any race or gender with age 20 or older 3. No history of any orthopedic, neurological, Pulmonary or psychological disorders, Cognitive impairments etc. 4. Had not performed physical activity in the previous three months. Exclusion criteria: 1. Grade III or grade IV heart failure according to the New York Heart Association (NYHA) Functional Classification. 2. Recent acute myocardial infarction; unstable angina; acute pericarditis. pulmonary hypertension; uncontrolled diabetes mellitus; Hypertensive crises or uncontrolled Hypertension or Pregnancy 3. Patients who had three consecutive absences during the intervention 4. Unable to answer or understand the gaming or exercise protocols and quality of life questionnaires and fulfil the exercise protocols, due to any severe cognitive deficit 5. Pain with ambulation or dizziness when standing or walking. 6. Contraindications to treadmill walking or VR gaming
Conditions Glaucoma, Primary Open Angle Glaucoma, P...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is a progressive optic neuropathy with retinal ganglion cell loss which leads to visual field loss. Open-angle glaucoma is the most common form of glaucoma. The aim of this pilot study is to evaluate the safety and effectiveness of the treatment of visual field defects using transcorneal electrical stimulation (TES) with the OkuStim 2 System in patients with primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Transcorneal electrical stimulation (TES) with the OkuStim 2 System — Retinal stimulation is achieved through transcorneal current application: using a thread electrode, a weak current (≤ 1mA) is introduced onto the surface of the eye, which spreads through the eye towards the retina.

Primary Outcomes

  • Difference in Humphrey visual field examination between the TES-treated group and the sham-treated group (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-02
Completion: 2028-06
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Okuvision GmbH
Collaborators: Interdisciplinary Center for Clinical Trials, University Medical Center Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Department of Ophthalmology, Sponsored by the German Federal Ministry of Education and Research (FKZ 13GW0732A)
Principal Investigators:
  • Katrin Lorenz, Prof. (PRINCIPAL_INVESTIGATOR) - Augenklinik und Poliklinik der Universitätsmedizin Mainz, Johannes Gutenberg-Universität Mainz
Contact Information
Study Contact:
Katrin Lorenz, Prof.
+49 6131 174069
katrin.lorenz@unimedizin-mainz.de
Katrin Lorenz, Prof.
+49 6131 173612
klinisches-studienzentrum-augenklinik@unimedizin-mainz.de
Augenklinik und Poliklinik der Universitätsmedizin Mainz, Johannes Gutenberg-Universität Mainz
Interventions
  • Device: Transcorneal electrical stimulation (TES) with the OkuStim 2 System — Retinal stimulation is achieved through transcorneal current application: using a thread electrode, a weak current (≤ 1mA) is introduced onto the surface of the eye, which spreads through the eye towards the retina.
Study Locations (1 sites)
Augenklinik und Poliklinik der Universitätsmedizin Mainz, Johannes Gutenberg-Universität Mainz, Mainz, 55131 Germany
Eligibility Criteria
Inclusion Criteria: 1. Willingness to participate in the study, the subjects signed and dated informed consent must be submitted before the start of the screening 2. Age ≥ 40 years 3. Primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma (according to the EGS criteria) in the study eye 4. Current progression in perimetry of at least 1.5 dB per year in the study eye and mean defect (MD) in the study eye between ≥ 6 and ≤ 12 dB (Octopus visual field) or ≤ -6 and ≥ -12 dB (Humphrey visual field) in the screening examination as the mean value of the two visual field examinations carried out as part of the screening (permitted deviation maximum 2 dB) 5. Visual acuity ≥ 0.2 decimal in the study eye (corresponds to a visual acuity of 0.7 logMAR) 6. The patient must master home stimulation after extensive training. 7. Ability of subject to understand the scope, significance and individual consequences of participation in the study 8. Ability of subject to give consent 9. If both eyes meet the inclusion/exclusion criteria, the eye with the higher MD is selected as the study eye. If the MD is the same in both eyes, the eye with the worse visual acuity will be selected as the study eye. If there is no difference between the eyes, the right eye will be selected as the study eye 10. Negative serum or urine pregnancy test at screening in women of childbearing potential. Participants are considered to be of nonchildbearing potential if they are postmenopausal and have not menstruated for at least 12 months prior to screening or if they are surgically sterile 11. Women of childbearing potential must agree to be abstinent or to use highly effective methods of contraception that result in a failure rate of less than 1% per year. This applies consistently throughout the duration of the treatment once you have given your consent to participate in the study. Exclusion Criteria: 1. Neovascularisations of any origin in the study eye 2. Condition after arterial or venous occlusions in the study eye 3. Condition after intraocular surgery in the last 3 months before the screening examination in the study eye 4. Acute (intra)ocular inflammation in any eye 5. Non-proliferative or proliferative diabetic retinopathy in the study eye 6. Condition after retinal detachment in the study eye 7. Dry age-related macular degeneration affecting the visual field in the study eye 8. Exsudative age-related macular degeneration in the study eye 9. Macular edema of any origin in the study eye 10. Other relevant retinal diseases in the study eye 11. Any form of corneal degeneration that limits vision in the study eye 12. Any disease other than glaucoma affecting the central 30° visual field in the study eye 13. No cataract surgery or other eye surgery may be planned for the patient in the study eye during the duration of the study (except laser trabeculoplasty) 14. Patients with active implants 15. General illnesses that are difficult to control/adjust and which, in the opinion of the investigator, could jeopardize regular study routines 16. Poor general condition according to the investigators assessment 17. Mental illness or dementia, that, in the opinion of the investigator, reduces the understanding of the study procedures and use of the Okustim 2 System 18. Simultaneous participation in another interventional study or past interventions whose effect may still be ongoing (30 days) 19. Breastfeeding women 20. Patients unable to consent 21. Previous enrolment in the TES-GPS study 22. Contraindications to the use of OkuStim 2 such as allergies/hypersensitivity to silver
Conditions Essential Hypertension, Type 2 Diabetes ...
Phase PHASE3
Enrollment 276
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: BR1019A — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019B — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019C — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019A-1 — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019B-1 — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019C-1 — Subjects take the investigational products once a day for 12 weeks.

Primary Outcomes

  • The change of mean sitting systolic blood pressure from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A-1+BR1019B+BR1019C-1 (12 weeks from Baseline Visit)
  • The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1 (12 weeks from Baseline Visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-05-21
Completion: 2026-12
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 276 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boryung Pharmaceutical Co., Ltd
Contact Information
Study Contact:
Shin-young Oh
+82-2-708-8000
syoh@boryung.co.kr
dr. Bambang Widyantoro, Sp.JP(K), PhD
(+62)21 1500034
cru@pjnhk.go.id
Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPD)
Seok-min Kang, M.D., Ph.D.
Severance Hospital
Interventions
  • Drug: BR1019A — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019B — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019C — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019A-1 — Subjects take the investigational products once a day for 12 weeks.
  • Drug: BR1019B-1 — Subjects take the investigational products once a day for 12 weeks.
Study Locations (3 sites)
Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPD), Jakarta, DKI Jakarta 11420 Indonesia
Severance Hospital, Seoul, South Korea
Severance Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Those with type 2 diabetes mellitus \& essential hypertension * Those who agree to discontinue existing antihypertensive and/or oral hypoglycemic drugs during the clinical trial * Those who are judged medically reasonable by investigator to be able to discontinue existing antihypertensive and/or oral hypoglycemic drugs(except for Metformin) during the clinical trial Exclusion Criteria: * Those who meet the following criteria * Those with a history of secondary hypertension or suspected secondary hypertension; (Including but not limited to; e.g., renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma and polycystic kidney disease, etc.) * Those with clinical significant orthostatic hypotension accompanied by symptoms * Those with diabetes mellitus taking renin inhibitors(Aliskiren) or moderate to severe renal impairment * Those with diabetic nephropathy taking ACE inhibitors * Those with type 1 diabetes mellitus, secondary diabetes mellitus, severe insulin-dependent diabetes, diabetic ketoacidosis or lactic acidosis * Those with uncontrolled, severe diabetic complications (Micro-vascular complications(e.g., nephropathy, retinopathy, neuropathy, etc.), Macro-vascular complications) * Diabetic coma or pre-coma

Retinal Blood Flow and Autoregulation

NCT05344274
Recruiting
Conditions Glaucoma
Phase PHASE4
Enrollment 90
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Indocyanine Green Angiography — Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
  • Biological: Isocapnic Oxygen — Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
  • Diagnostic Test: Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) — Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates

Primary Outcomes

  • Autoregulation of retinal blood flow (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-05-23
Completion: 2027-09
Eligibility
Age: 18 Years – 88 Years
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Maryland, Baltimore
Contact Information
Study Contact:
Osamah Saeedi, MD, MS
(410) 328-5929
osaeedi@som.umaryland.edu
Interventions
  • Diagnostic Test: Indocyanine Green Angiography — Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
  • Biological: Isocapnic Oxygen — Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
  • Diagnostic Test: Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) — Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
Study Locations (4 sites)
University of Maryland Faculty Physicians, Inc, Baltimore, Maryland 21201 United States
University of Maryland Medical Center, Baltimore, Maryland 21201 United States
University of Maryland, Baltimore, Baltimore, Maryland 21201 United States
Food and Drug Administration (FDA), Silver Spring, Maryland 20903 United States
Eligibility Criteria
Inclusion Criteria: 1. age over 18 years 2. open angle in gonioscopy (grade 3 or 4 in Shaffer classification) 3. refractive error within the range of +3.00 to -8.00 diopters (4) best-corrected visual acuity 20/25 or better (5) Individuals recruited will be in one of the 3 groups: 1\) Early Glaucoma as per Hodapp-Anderson-Parrish Criteria (54). Early glaucoma subjects specifically with visual field defects restricted to one side of the horizontal midline will be selected to allow for comparison of rates of progression in both hemifields. Individuals will need to be off of glaucoma medications for four weeks to participate in the study. 2) Pre-perimetric glaucoma defined as the presence of glaucomatous optic nerve damage (e.g., focal notching, rim thinning), RNFL defect, and the absence of a definite glaucomatous visual field defect using standard automated perimetry at the three most recent consecutive examinations. A glaucomatous visual field defect is defined as either 3 or more abnormal points with a P\<0.05, of which at least 1 point has a pattern standard deviation (PSD) of P\<0.01; or a PSD of P\<0.05; or glaucoma hemifield test values outside the normal limits. (55,56) 3) Control group - A subject with no family history of glaucoma who has the following: a) OCT with all four quadrants within the normal range for age-matched controls, b) reliable visual fields with glaucoma hemifield test within normal limits and determined to be normal by a glaucoma specialist, and c) cup-to-disc ratio of 0.4 or lower and asymmetry of the cup to disc ratio no greater than 0.1 as determined by a glaucoma specialist. Control subjects will be age matched to the early glaucoma subjects. Exclusion Criteria: 1. corneal abnormalities or other conditions preventing reliable applanation tonometry 2. retinal disease affecting retinal nerve fiber layer thickness such as vitreomacular traction as determined by a glaucoma specialist 3. secondary glaucoma 4. history of prior ocular surgery other than uncomplicated cataract surgery or laser trabeculoplasty 5. inability to safely be off of glaucoma medications for 4 weeks 6. inability to obtain OCT angiography data due to excessive eye motion or inability to fixate 7. unreliable visual fields 8. any history of smoking in the past 6 months 9. cataract greater than lens opacity classification system (LOCS) II Grade≥2 10. diagnosis of diabetes, hypertension, or other known vascular disorder such as vasculitis
Conditions Variceal Bleeding, Portal Hypertension
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Esophageal and gastric variceal bleeding (EGVB) is a severe complication of portal hypertension (PH), characterized by high bleeding volume, high rebleeding rate, and high mortality. In recent years, endoscopic treatment has significantly improved therapeutic efficacy and patient survival. However, due to substantial individual variations among patients, individualized stratified management is crucial. For special populations with cirrhotic portal hypertension, clear management guidelines and clinical research evidence are lacking. The incidence of non-cirrhotic portal hypertension is increasing year by year; it has complex etiologies, lacks specific symptoms and imaging features, and poses diagnostic challenges. Currently, multi-omics research on portal hypertension is insufficient. The integration of multi-omics technologies, including genomics, radiomics, metabolomics, and gut microbiota, holds promise for a more comprehensive understanding of the pathogenesis. With continuous improvements in multi-modal medical data fusion technology, there is an urgent need to develop clinical decision support systems by combining standardized multi-omics databases with artificial intelligence techniques, thereby enhancing clinical decision-making capabilities and prognostic assessment. This study aims to expand the established portal hypertension biobank by extending the temporal depth of clinical cohort data and diversifying sample types.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Procedure: Endoscopic treatment — Endoscopic treatment including ligation and cyanoacrylate injection

Primary Outcomes

  • One-year rebleeding (Within 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-16
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Zhongshan Hospital
Contact Information
Study Contact:
Xiaoquan Huang, M.D.
86-18801733835
huang.xiaoquan@zs-hospital.sh.cn
Xiaoquan Huang, M.D.
86-18801733835
huang.xiaoquan@zs-hospital.sh.cn
Zhongshan Hospital, Fudan University
Interventions
  • Procedure: Endoscopic treatment — Endoscopic treatment including ligation and cyanoacrylate injection
Study Locations (1 sites)
Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality 200000 China
Eligibility Criteria
Inclusion Criteria: 1. Clinically diagnosed with portal hypertension complicated by esophagogastric varices. 2. Underwent abdominal CT examination Exclusion Criteria: 1. Imaging or endoscopic evidence demonstrating absence of esophageal and/or gastric varices. 2. CT image quality not meeting requirements or incomplete medical history data.
Conditions ART, Pre-Eclampsia
Phase PHASE3
Enrollment 1164
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Drug: Aspirin — Experimental drug administrated orally
  • Drug: Placebo — Treatment for the control group

Primary Outcomes

  • Effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo in the prevention of preterm (<37 weeks of gestation) preeclampsia (Up to 9 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-08-02
Completion: 2029-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1164 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Toulouse
Principal Investigators:
  • Christophe VAYSSIERE, MD (PRINCIPAL_INVESTIGATOR) - University Hospital, Toulouse
Contact Information
Study Contact:
Paul GUERBY, MD
5 67 77 12 33
guerby.p@chu-toulouse.fr
Delphine DUCHANOIS, Midwife
5 67 77 12 33
duchanois.d@chu-toulouse.fr
Pierre-Emmanuel BOUET, MD
CHU Angers
Interventions
  • Drug: Aspirin — Experimental drug administrated orally
  • Drug: Placebo — Treatment for the control group
Study Locations (21 sites)
CHU Angers, Angers, France
CHU Bordeaux, Bordeaux, France
CHU Clermont-Ferrand, Clermont-Ferrand, France
CHU Dijon-Bourgogne, Dijon, France
CHU Lille, Lille, France
HCL - Groupement Hospitalier Est, Hôpital Femme Mère Enfant, Lyon, France
AP-HM Hôpital de la Conception, Marseille, France
AP-HM Hôpital Nord, Marseille, France
CHU Montpellier, Montpellier, France
CHRU Nancy, Nancy, France
Eligibility Criteria
Inclusion Criteria: * Nulliparous women aged 18 years or more * Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor * Singleton pregnancy * Evolutive pregnancy between 9 and 14 weeks of gestation * Women affiliated to a French Social Security Insurance or equivalent social protection * Written informed consent Exclusion Criteria: * Major fetal abnormality * Regular treatment with aspirin (including antiphospholipid syndrome) * Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia) * Women protected by law. * Women included in another interventional study.
Conditions Esophagogastric Varices, Portal Hyperten...
Phase Not Applicable
Enrollment 1384
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study is a single-center, prospective cohort study based on real-world data. Patients with portal hypertension and esophagogastric varices were enrolled and divided into an endoscopic treatment group and a non-endoscopic treatment group (including patients receiving medical therapy, interventional procedures, or surgical treatment) according to whether they underwent endoscopic intervention. Baseline data, serum metabolites, CT imaging and endoscopic images, liver biopsy pathology, and other multi-omics data were integrated for both groups. Patients were followed up to compare adverse events after variceal treatment, including rebleeding and its causes, hepatic encephalopathy, ascites, subsequent treatments (such as regular endoscopic therapy, NSSB, and TIPS), and survival outcomes. Clinical characteristics of portal hypertension attributed to different etiologies, including hepatitis B, autoimmune liver disease, schistosomiasis, hematological disorders, and chemotherapy-induced liver injury, were compared. The efficacy and safety of endoscopic and interventional treatments for esophagogastric varices were evaluated. Factors influencing rebleeding rates among different treatment groups were analyzed, and reasons for inclusion in different groups were discussed.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Survival (At 1, 2, 6, and 12 months post-treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-20
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1384 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Zhongshan Hospital
Principal Investigators:
  • Shiyao Chen, Ph.D. (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Xiaoquan Huang, M.D.
86-18801733835
huang.xiaoquan@zs-hospital.sh.cn
Xiaoquan Huang, M.D.
18801733835
huang.xiaoquan@zs-hospital.sh.cn
Zhongshan Hospital, Fudan University
Interventions
N/A
Study Locations (1 sites)
Zhongshan Hospital, Fudan University, Shanghai, China
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of portal hypertension with esophagogastric varices. * Underwent abdominal CT and gastroscopy examinations. Exclusion Criteria: * Presence of peptic ulcer, gastric tumor, or other causes of gastrointestinal bleeding confirmed by imaging or gastroscopy. * CT images of inadequate quality or incomplete medical history data.